Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 5/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681442 | 0.80 | CPN1 (0.33) | CPN1CPB2MEN1ALDH1A1KMT2A | |
| SCHEMBL13804436 | 0.80 | CPN1 (0.49) | CCR2CPN1CPB2GAA | |
| SCHEMBL26203697 | 0.79 | DPP4 (0.33) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL21573595 | 0.78 | MEN1 (0.31) | MEN1ALDH1A1KMT2A | |
| SCHEMBL1109055 | 0.78 | CPN1 (0.40) | CCR2CPN1CPB2GAAOPRL1 | |
| SCHEMBL26203723 | 0.77 | — | — | |
| SCHEMBL18161032 | 0.77 | GAA (0.33) | CPN1CPB2GAAOPRL1DPP4 | |
| SCHEMBL25583932 | 0.77 | — | — | |
| SCHEMBL19999882 | 0.75 | — | — | |
| SCHEMBL21431293 | 0.75 | CCR2 (0.32) | CCR2OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229839-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229839-A1 | Factor XIa Inhibitors | F11, SERPINC1, TFPI | CCR2 1977/4885CPN1 2208/4885CPB2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.